Abstract
Final Results from the Multicenter, Open-Label, Phase II GIBB Study of Obinutuzumab+Bendamustine in Previously Untreated Patients with Chronic Lymphocytic Leukemia
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have